KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 67.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,286 shares of the specialty pharmaceutical company’s stock after buying an additional 3,328 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in KalVista Pharmaceuticals were worth $96,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of KALV. Capital World Investors acquired a new stake in KalVista Pharmaceuticals in the 1st quarter valued at about $17,370,000. Great Point Partners LLC acquired a new position in shares of KalVista Pharmaceuticals in the 2nd quarter valued at $15,768,000. Entropy Technologies LP purchased a new stake in KalVista Pharmaceuticals in the first quarter valued at $121,000. The Manufacturers Life Insurance Company boosted its stake in KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after acquiring an additional 3,314 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after purchasing an additional 944 shares during the last quarter.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $10.27 on Friday. The stock has a market capitalization of $433.27 million, a P/E ratio of -3.03 and a beta of 0.89. The company’s fifty day moving average is $11.69 and its two-hundred day moving average is $12.11. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.21 and a 1 year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. Sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.35 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on KALV. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th.

Insider Activity at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 2,135 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now owns 83,745 shares of the company’s stock, valued at $1,038,438. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now owns 83,745 shares in the company, valued at approximately $1,038,438. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total value of $170,722.15. Following the completion of the transaction, the chief executive officer now directly owns 242,527 shares of the company’s stock, valued at approximately $2,912,749.27. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,804 shares of company stock worth $372,112 over the last 90 days. Company insiders own 12.30% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).